Wheeler Bio, a U.S.-based company that specializes in high science and high-touch contract development and biomanufacturing, has announced a strategic partnership with Mitsubishi Corporation. This partnership is meant to help Wheeler expand its presence and business development activities in the Asia-Pacific region. As part of this cooperation, Mitsubishi is investing in Wheeler’s Series A-1 financing. Mitsubishi will use its wide regional network, strong industry connections, and extensive commercial experience to help biotech companies in Japan, South Korea, India, Singapore, Taiwan, and China access U.S.-based development and cGMP manufacturing services. Mitsubishi has been named Wheeler’s exclusive partner in the region, and its focus will be on building new client relationships and helping biologics developers connect with Wheeler’s AI/ML-enabled ModularCMC platform and its advanced cGMP manufacturing facility in Oklahoma City. Wheeler Bio’s ModularCMC platform is designed to speed up the process of moving from discovery to clinical development for antibody-based therapies. It offers speed, flexibility, and scalability, along with a high-touch approach that is grounded in scientific rigor, transparency, and collaborative partnership.
Health Technology Insights: Purdue Pharma Plan of Reorganization Receives Overwhelming Creditor Support
Takahiro Tokuda, the Chief Operating Officer of Mitsubishi Corporation’s Healthcare Division, said that the company has been actively involved in the pharmaceutical CDMO market and strongly believes that Wheeler Bio’s services provide significant value to clients. He added that this partnership is expected to speed up the development of biopharmaceutical innovations in the Asia-Pacific region and ultimately improve patient outcomes.
Health Technology Insights: Genesys Cloud AI Enhances Patient Care at Steinberg Diagnostic Medical Imaging
Patrick Lucy, President and Chief Executive Officer of Wheeler Bio, thanked Mitsubishi for its investment and partnership. He emphasized that Mitsubishi’s long-standing experience in biologics contract manufacturing will be a valuable asset as Wheeler grows. Lucy also highlighted that this collaboration will help Wheeler extend its reach, strengthen its business development efforts, and support the increasing need for U.S.-based biomanufacturing solutions.
Through this partnership, Wheeler Bio and Mitsubishi aim to connect Asia-Pacific biotech innovators with advanced U.S. manufacturing solutions, offering full-service support for antibody-based therapeutics. This initiative shows Wheeler’s commitment to combining cutting-edge technology with personalized service to help move therapies from the lab to clinical development more quickly.
By combining Mitsubishi’s regional insights with Wheeler’s ModularCMC platform, the partnership aims to simplify the development process, create new business opportunities, and build a scalable system for delivering high-quality biologics manufacturing services with transparency, agility, and scientific precision.
Health Technology Insights: Praia Health Launches AI Tool Boosting Patient Conversions
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
